Nice work
Article Abstract:
The National Institute for Clinical Excellence (Nice) has decided against recommending a flu drug, Relenza from Glaxo Wellcome, to be prescribed through the National Health Service. This decision is seen as a threat by some other drugs companies, which view Nice as an additional barrier to selling their products. Spending on drugs can mean savings elsewhere, but it is easier to target drugs companies than patients, who are also voters. Nice is able to ensure that healthcare spending offers value for money, but short-term cost-containment can create problems over the longer term.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Pharmaceuticals: punishment unjustified
Article Abstract:
Astra has seen a drop in its share price following publicity about legal action over a competitor which has ended. The company was involved in action against Byk Gulden over Pantoprazole which Astra claims infringed its Losec patent. A previous action by Astra against Takeda led to a small royalty payment and two development drugs but Byk does not have drugs that Astra requires. Pantoprazole is not seen as a serious threat to Losec, and Astra is seen as fundamentally sound despite the share price drop.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Bioglan's woes blamed on management
Article Abstract:
Bioglan Pharma's GBP35.7 mil losses in 1st-half 2001 and its withdrawal from the purchase of the skincare operations of Bristol Myers Squibb are largely due to management failings. Managers were too focused on the acquisition plans, to the detriment of existing operations.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Hard to resist. Pharmaceuticals: catch the merger wave. Pharmaceuticals and healthcare
- Abstracts: A nibble of your nest egg. Phasing out pension stress
- Abstracts: Women's networks a success. Recruiting with the best
- Abstracts: A practical view: understanding and serving the older client. The legal, regulatory, and compliance-related implications of using soft-dollar arrangements
- Abstracts: Making acquisitions work. Leadership passages: being part of an acquisition or merger. Doubling in size, post-merger, SBC learned to consolidate functions quickly and effectively